A series of personal injury suits filed in Los Angeles earlier this month alleges that a charity established by the financier Michael Milken, in conjunction with prostate cancer researchers nationwide, engaged in systematic promotion of PC-Spes, a “nutraceutical” that was sold as a mixture of Chinese herbs, but was laced with prescription drugs.
Also in this 12-page issue: ASCO urges freeze of Medicare payments for chemotherapy at 2004 levels for next two years.
NCI director creates four new deputy director positions to manage the Institute.
Five NCAB members complete terms.
Breast surgeon and advocate Susan Love weds surgeon Helen Cooksey in San Francisco.
Funding opportunities listed.
NIH Director Zerhouni to discuss Roadmap initiatives Feb. 27.
Trending Stories
- The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe - As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick lab
The job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded - Pancreatic cancer breakthrough came from smart scientists making smart bets—not from politicization of science
- At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer
- Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival
- Proposed OMB rule aims at the heart of the U.S. research enterprise—and scientists are fighting back
“The question isn’t whether politics will influence research. Under this proposal, that’s the point. That’s their goal.”
